FY2022 EPS Estimates for Halozyme Therapeutics, Inc. Cut by Analyst (HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Research analysts at Piper Jaffray Companies decreased their FY2022 EPS estimates for shares of Halozyme Therapeutics in a research note issued on Tuesday, November 6th. Piper Jaffray Companies analyst J. Catanzaro now expects that the biopharmaceutical company will post earnings of $1.18 per share for the year, down from their prior estimate of $1.31. Piper Jaffray Companies currently has a “Neutral” rating on the stock.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.04. The business had revenue of $25.60 million for the quarter, compared to analysts’ expectations of $30.42 million. Halozyme Therapeutics had a net margin of 16.24% and a return on equity of 18.82%. The business’s revenue for the quarter was down 59.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.02 EPS.

Several other equities research analysts have also recently issued reports on the stock. ValuEngine cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Cantor Fitzgerald set a $27.00 price target on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Tuesday. Finally, BidaskClub cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $20.78.

Halozyme Therapeutics stock opened at $16.25 on Thursday. Halozyme Therapeutics has a 12-month low of $14.33 and a 12-month high of $21.48. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of 36.11 and a beta of 1.88. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.43 and a current ratio of 3.49.

In other Halozyme Therapeutics news, major shareholder Randal J. Kirk sold 1,194,462 shares of Halozyme Therapeutics stock in a transaction on Thursday, August 23rd. The shares were sold at an average price of $17.65, for a total value of $21,082,254.30. Following the completion of the transaction, the insider now owns 3,562,388 shares of the company’s stock, valued at $62,876,148.20. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Randal J. Kirk sold 303,168 shares of Halozyme Therapeutics stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $17.36, for a total transaction of $5,262,996.48. Following the completion of the transaction, the insider now directly owns 3,562,388 shares of the company’s stock, valued at approximately $61,843,055.68. The disclosure for this sale can be found here. Insiders have sold 2,793,946 shares of company stock valued at $49,250,429 in the last three months. Corporate insiders own 16.80% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in HALO. MERIAN GLOBAL INVESTORS UK Ltd acquired a new position in Halozyme Therapeutics in the third quarter worth $21,690,000. BlackRock Inc. boosted its holdings in Halozyme Therapeutics by 5.7% in the second quarter. BlackRock Inc. now owns 12,242,431 shares of the biopharmaceutical company’s stock worth $206,530,000 after purchasing an additional 659,763 shares during the period. JPMorgan Chase & Co. boosted its holdings in Halozyme Therapeutics by 12.5% in the third quarter. JPMorgan Chase & Co. now owns 3,601,604 shares of the biopharmaceutical company’s stock worth $65,441,000 after purchasing an additional 400,008 shares during the period. First Light Asset Management LLC boosted its holdings in Halozyme Therapeutics by 76.9% in the second quarter. First Light Asset Management LLC now owns 889,729 shares of the biopharmaceutical company’s stock worth $15,010,000 after purchasing an additional 386,700 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in Halozyme Therapeutics in the first quarter worth $7,167,000. 84.63% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

See Also: Book Value Per Share – BVPS

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply